Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16730658 | 0.93 | MAPT (0.49) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL23838607 | 0.86 | KMT2A (0.54) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL9823025 | 0.85 | NPC1 (0.75) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL24920215 | 0.80 | NPC1 (0.54) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL16660774 | 0.80 | KMT2A (0.48) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL26260604 | 0.79 | NPC1 (0.62) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL16646641 | 0.79 | ALDH1A1 (0.47) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL24920314 | 0.77 | NPC1 (0.51) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL9822779 | 0.75 | TDP1 (0.72) | NPC1RAB9AMEN1KMT2AALDH1A1 | |
| SCHEMBL9822885 | 0.75 | NPC1 (0.53) | NPC1RAB9AMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3925627-A1 | DRUG-CONJUGATES AND USES THEREOF | Concortis Biosystems, Corp (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3057610-B1 | DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS | SORRENTO THERAPEUTICS INC (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-2849790-B1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | CONCORTIS BIOSYSTEMS CORP (US) | 2019-04-10 | — | — | EP | disclosed |
| US-9801951-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2015-04-16 | — | — | US | disclosed |
| US-20150105540-A1 | DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS | SORRENTO THERAPEUTICS INC. (US) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105539-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | PAICS, CES2, DNPEP | NPC1 635/4885RAB9A 1067/4885MEN1 1452/4885 |
| US-20150105540-A1 | DRUG-CONJUGATES WITH A TARGETING MOLECULE AND TWO DIFFERENT DRUGS | ERBB2, ABCG2, DYNLL2 | NPC1 2589/4885RAB9A 627/4885MEN1 3587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.